Alzheimer’s Biomarker Development Hampered By ‘Limited’ Commercial Incentives
Executive Summary
Eli Lilly executive suggests the public sector may need to come up with a solution to drive innovation if the private sector does not do so.
You may also be interested in...
As US FDA Settles Into Teleworking, Will Application Reviews Be Affected?
Productivity may suffer under coronavirus-mandated telework despite workforce diligence, experts say.
US FDA Freezes Inspections And Outside Meetings. Will Review Goal Dates Stay Put?
Sponsors have been asked to switch to teleconferences with FDA staff as the agency prepares for more of its employees to work from home.
Alzheimer’s Drug Coverage Issues Move To Forefront With Biogen’s Plan To Seek Approval
Any product would be mostly covered by Medicare, but because the potential patient population will likely be 'substantial,' payers will likely 'closely scrutinize' these drugs, Duke Margolis white paper observes.